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Introduction {#sec1}
============

Biliary tract cancers (BTCs) include intra- and extrahepatic cholangiocarcinoma, gallbladder carcinomas, and ampullary carcinomas. The majority (80%--90%) of patients present with advanced disease, and each year 139,000 people die of BTC around the world, including 12,000 in the US ([@bib7], [@bib26]). The incidence of the disease varies globally, with highest rates in northeastern Thailand and neighboring Laos and Cambodia where liver fluke infestations are endemic ([@bib7]). Furthermore, for reasons that are presently unknown, the incidence of intrahepatic cholangiocarcinoma is increasing in the western world ([@bib39]). Systemic chemotherapy has only modest activity in the metastatic setting, with gemcitabine plus cisplatin the standard of care, and there are currently no approved second-line or targeted therapies for BTC. Consequently, the median overall survival for these patients is approximately 12 months ([@bib42]).

Initial sequencing studies aiming to characterize the genomic landscape of BTCs ([@bib9], [@bib17], [@bib24], [@bib29]) identified a series of recurrently mutated genes, including loss-of-function mutations in the tumor suppressors *TP53* and *SMAD4* and the epigenetic modifiers *ARID1A*, *ARID2,* and *BAP1*, whereas activating mutations in *KRAS*, *PIK3CA,* and *NRAS* were the most common oncogenic events ([@bib29]). More recent studies identified fusions involving *PRKACA* and *PRKACB* as other potential driver events ([@bib29]), as well as mutations in *ROBO2*, *RNF43* ([@bib32]), *RASA1*, *STK11,* and *MAP2K4* ([@bib17]). These studies also identified potential therapeutically exploitable targets including mutations and amplifications of members of the ERBB family of receptor tyrosine kinases ([@bib24]), *IDH1* mutations ([@bib4]), and *FGFR2* fusions ([@bib3]); however, in many cases it remains to be determined whether these genomic alterations can be exploited for therapeutic benefit. To test this, reliable models harboring endogenous alterations in these potential targets are needed. In this regard, cell lines represent powerful models to study cancer biology and assess drug response.

Although a number of BTC cell lines have been established, their genomic profiles have not been extensively characterized and compared with that of primary BTCs. In this study, we comprehensively profiled 22 BTC cell lines by exome sequencing, copy number analysis, and RNA-seq analysis. We found that the most frequently observed genomic alterations in primary BTCs are preserved in cell lines validating their use as accurate model systems to study this disease. In addition, we identified two distinct molecular subsets of BTC cell lines that differ in expression of EMT genes and importantly demonstrate that these signatures are also evident in patient-derived organoid models and primary BTCs. We also demonstrate that the MAPK signaling pathway is deregulated by multiple mechanisms in BTC and identify a number of potential actionable drug targets for this disease.

Results {#sec2}
=======

Exome Sequencing of Biliary Cancer Cell Lines {#sec2.1}
---------------------------------------------

A panel of 22 BTC cell lines derived from tumors from distinct anatomical locations within the biliary tree was assembled from international cell repositories and individual investigators ([Table S1](#mmc1){ref-type="supplementary-material"}). The panel comprised the majority of BTC lines described in the literature ([@bib13], [@bib12], [@bib18], [@bib20], [@bib21], [@bib22], [@bib27], [@bib47]), including two cell lines, KKU-M055 and KKU-M213, derived from liver-fluke-associated intrahepatic cholangiocarcinoma ([@bib31], [@bib40]).

The total number of mutations (SNVs + InDels) ranged from 315 to 623 (mean 394) across the cell lines ([Figures 1](#fig1){ref-type="fig"}A--1C and [Table S2](#mmc2){ref-type="supplementary-material"}). The average frequency of Indels in cell lines (0.27 InDels/Mb, range 0.16--0.42 InDels/Mb) was similar to that observed in primary cancers (0.32 InDels/Mb). Comparatively, the average mutation rate for cell lines (5.0 SNVs/Mb, range 3.9--7.9 SNVs/Mb) was higher than that observed in primary BTCs (mean 2.6 SNVs/Mb). No hypermutated cell lines (\>25 mutations/Mb) were identified in the panel, consistent with the low frequency (5%) of hypermutated cases in primary BTCs ([@bib29]).Figure 1Mutation Burden and Mutational Signatures in 22 Biliary Cancer Cell Lines(A) Counts of total mutations, (B) SNVs, and (C) InDels in BTC cell lines.(D) Percentage of nucleotide transitions and transversions.(E and F) Representative cell lines harboring (E) mutational signature 1 (OZ cells) and (F) mutational signature 2 (HuH28 cells). ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; GB, gallbladder carcinoma; AC, ampullary cancer; LF, liver-fluke-associated intrahepatic cholangiocarcinoma.

The dominant somatic substitution pattern observed in primary BTCs are C \> T/G \> A transitions that are enriched at CpG dinucleotides, followed by T \> C/A \> G transitions and C \> A/T \> G transversions ([@bib2], [@bib29]). This pattern is similar in fluke- and non-fluke-derived tumors ([@bib6]). A similar distribution of somatic substitution patterns was observed in BTC cell lines, with C \> T (0.49 ± 0.03) transitions as the dominant pattern observed, followed by T \> C (0.15 ± 0.02) transitions and C \> A transversions (0.14 ± 0.04) ([Figure 1](#fig1){ref-type="fig"}D).

In primary BTC, two predominant mutational signatures have been identified: (A/C/G)CG\>(A/C/G)TG previously defined as Signature 1 by Alexandrov et al. ([@bib2]), which is the result of an endogenous mutational process initiated by spontaneous deamination of 5-methylcytosine, and TC(A/C/T)\>TG(A/C/T) and TCN \> TTN, which is similar to the previously defined APOBEC-associated signature (Signature 2) ([@bib2]). Although the predominant signature in BTC cell lines was Signature 1 ([Figure 1](#fig1){ref-type="fig"}E), we identified one cell line (HuH28, intrahepatic) with the classical APOBEC signature ([Figure 1](#fig1){ref-type="fig"}F), which was also the cell line harboring the highest mutational load.

Comparison of the Most Frequently Mutated Genes in Primary BTCs and BTC Cell Lines {#sec2.2}
----------------------------------------------------------------------------------

To determine if the genes most frequently mutated in primary BTCs are reflected in BTC cell lines, we compared the frequency of mutations with that reported by Nakamura et al. in which 13 significantly mutated genes were identified from sequencing 260 primary BTCs ([@bib29]). Compared with primary disease, the mutational frequency of several known oncogenes and tumor suppressor genes including *TP53* (25.9% vs 63.6%), *KRAS* (18.0 vs 40.9%), and *SMAD4* (8.8% vs 18.2%) were higher in cell lines ([Figure 2](#fig2){ref-type="fig"}A). Nevertheless, we observed a strong correlation between the most frequently mutated genes in primary cancers and cell lines (Pearson\'s *R* = 0.962), demonstrating that although cell lines have a higher mutational frequency of major oncogenes and tumor suppressor genes, the relative proportion of these mutations is similar to that observed in primary disease ([Figure 2](#fig2){ref-type="fig"}B).Figure 2Comparison of the Mutation Landscape of BTC Cell Lines with Primary BTCs and Validation of *TP53* Mutation Status(A) Oncoplot of the most significantly mutated genes in primary BTC.(B) Pearson\'s correlation of the frequency of mutations in cell lines compared with primary cancers from the ICGC (International Cancer Genomics Consortium). ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; GB, gallbladder carcinoma; AC, ampullary cancer; LF, liver-fluke-associated intrahepatic cholangiocarcinoma.(C) TP53 mRNA expression in *TP53* wild-type and mutant BTC cell lines determined by RNA-seq. Groups were compared using an unpaired t test.(D) TP53 protein expression determined by immunohistochemistry in *TP53* wild-type and mutant BTC cell lines. Scale bar 50 μM.

Functional Validation of Specific Mutations in BTC {#sec2.3}
--------------------------------------------------

To validate the functionality of specific mutations, we examined corresponding mRNA expression of genes harboring truncating mutations by analysis of RNA-seq data generated for each cell line. As expected, cell lines harboring truncating *TP53* mutations had significantly lower *TP53* mRNA expression compared with *TP53* wild-type cell lines or cell lines harboring *TP53* point mutations ([Figure 2](#fig2){ref-type="fig"}C). Furthermore, immunohistochemical staining of the cell lines revealed high TP53 protein expression in mutant cell lines compared with wild-type lines or lines harboring truncating mutations ([Figure 2](#fig2){ref-type="fig"}D). Similarly, the single cell line harboring a homozygous inactivating mutation in *BAP1* (TFK-1) had the lowest level of BAP1 mRNA expression among the cell lines ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We also identified three cell lines harboring mutations in the WNT pathway (KKU-M055, *APC* frameshift; TGBC18TKB, *CTNNB1 T41A*; and SNU-869, *CTNNB1 S45P*). KKU-M055 cells also harbored a deletion of *APC* (Chr5 q22.2) consistent with loss of heterozygosity. As expected, these three lines had markedly higher Wnt reporter (TOPFLASH) activity, and expression of the Wnt target gene, *AXIN2*, compared with wild-type lines ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Notably, inactivating mutations in the E3 ubiquitin ligase *RNF43* have also been reported to enhance canonical Wnt signaling due to failure to degrade FZD receptors on the cell surface ([@bib19]), and we identified one cell line, Sk-ChA-1, harboring a biallelic inactivating *RNF43* mutation, which also had low levels of *RNF43* mRNA expression ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Surprisingly, however, TOPFLASH activity and Wnt target gene expression was not elevated in this line ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B), and Sk-ChA-1 cells were not preferentially sensitive to exogenous Wnt ligand ([Figure S2](#mmc1){ref-type="supplementary-material"}C), collectively indicating that the inactivating *RNF43* mutation in this line does not activate the Wnt pathway.

DNA Copy Number Changes and Identification of Focal Regions of Amplification and Deletion in BTC Cell Lines {#sec2.4}
-----------------------------------------------------------------------------------------------------------

To investigate changes in DNA copy-number, we utilized Illumina OmniExpress SNP arrays. The most commonly deleted genomic regions were chromosome *8p* and chromosome *18*, whereas the most commonly gained regions were *5p, 7p, 17q,* and chromosome *20*. We also identified focal regions significantly altered by DNA copy-number alterations in cell lines using GISTIC. Significantly amplified genes across the cell lines were *KRAS* (*12p12.1*), *SLCO1B* (*12p12.2*), *ALG10* (*12p11.1*), *hsa-mir-720/hsa-mir-1263/BCHE* (*3q26.1*), and *POU5F1B* (*8q24.21*), and significantly deleted regions were *CDKN2A/B* (*9p21.3*), *FHIT* (*3p14.2*), *WWOX* (*16q23.1*), *MACROD2* (*20p12.1*), and *TPRG1* (*3q28*) ([Figure 3](#fig3){ref-type="fig"}A).Figure 3Genome-Wide DNA Copy Number Alterations in BTC Cell Lines(A) DNA copy-number gains and losses in 22 BTC cell lines deduced using OmniExpress arrays and the OncoSNP tool for characterizing copy number alterations. Significant regions of chromosomal loss (dark blue) and gain (dark red) deduced using GISTIC2.0. Focally deleted and amplified genes in specific cell lines are indicated in light blue and red, respectively.(B and C) Corresponding mRNA expression of representative (B) deleted and (C) amplified genes determined by RNA-seq.

We also performed an analysis in which we determined the extent of overlap of the 33 homozygously deleted and 22 focally amplified genes identified in \>2 primary BTCs by Nakamura et al. ([@bib29]). Of the 33 homozygous deleted genes, 16 (47%) were also deleted in one or more cell line. All of these genes were located at chromosome *9p21.3* and included *CDKN2A* and *CDKN2B*. Confirming the deletion of *CDKN2A* and the adjacently located *CDKN2B*, mRNA expression of these genes was significantly lower in cell lines harboring homozygous deletions ([Figure 3](#fig3){ref-type="fig"}B). In comparison, 20 of the 22 amplified genes identified in primary disease were found to be also amplified in at least one BTC cell line (copy number ≥5), of which five genes (22%) had copy numbers ≥ 7 in one or more cell lines (*MYC, YEATS4, CCND3, IKBKB, KRAS*) ([Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc3){ref-type="supplementary-material"}). Notably, four of these five focally amplified genes displayed corresponding increases in mRNA expression ([Figure 3](#fig3){ref-type="fig"}C).

Unsupervised Clustering of Cell Lines Based on Gene Expression Identifies Two Major Subgroups that Differ in Epithelial and Mesenchymal Characteristics {#sec2.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------

We next performed RNA-seq analysis on the cell lines. Unsupervised clustering based on expression of all genes separated the cell lines into two major groups, comprising 7 and 13 cell lines ([Figure 4](#fig4){ref-type="fig"}A). Gene set enrichment analysis of the 411 genes differentially expressed between these groups identified the hallmarks epithelial-mesenchymal transition (EMT), mitotic spindle, and hypoxia with the most significant enrichment scores in the smaller cluster, whereas cholesterol homeostasis, IFN alpha and gamma response, and early and late estrogen response were significantly enriched in the larger cluster ([Figure 4](#fig4){ref-type="fig"}B). Consistent with enrichment of the EMT hallmark, expression of mesenchymal genes *CTGF, FLNA, FN1, TGFβ1,* and *ZEB1* were higher in the smaller cluster (mesenchymal cluster), whereas expression of multiple drivers (*ELF3, KLF5, EHF*) and markers of epithelial differentiation (*CDH1, EPCAM, KRT19, KRT8, VILL*) and tight junction components (*CGN, CRB3, CLDN4, CLDN7, F11R, TJP3*) were more highly expressed in the "epithelial cluster" ([Figure 4](#fig4){ref-type="fig"}A). Notably, four out of seven lines in the mesenchymal cluster were derived from metastatic gallbladder cases. To determine if these transcriptional differences translated to histological differences, representative cell lines from each cluster were grown as xenografts. All three lines from the mesenchymal cluster grew as poorly differentiated tumors with no glandular structure, whereas the three lines from the epithelial cluster grew as moderately differentiated tumors with clear evidence of glandular morphology ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, the majority of cell lines from the mesenchymal cluster grew primarily as single cells or with spindle-like morphology *in vitro*, compared with cell lines from the epithelial cluster where many grew in patches of closely adhered cells ([Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}).Figure 4Basal Gene Expression Profiles of BTC Cell Lines Determined by RNA-seq Analysis(A) Unsupervised cluster analysis of 20 BTC cell lines based on basal level of expression of all genes determined by RNA-seq analysis. Heatmap shows the 411 genes with significant differential expression between the two clusters. RNA-seq analyses of KKU-M055 and KKU-M213 cells were performed at a later time by a different method and were not included in the analysis due to batch effects.(B) Gene set enrichment analysis of 411 differentially expressed genes between the two clusters.(C) Histology of representative BTC cell lines from epithelial and mesenchymal clusters following growth as xenografts. Scale bar 100 μM.(D) Expression of epithelial and mesenchymal genes in patient-derived biliary cancer organoids from patients with well-differentiated (WD), moderately differentiated, (MD) or moderate-to-poorly differentiated (MD/PD) tumors. Values shown are from microarray analyses of these organoids ([GSE112408](ncbi-geo:GSE112408){#intref0020}).

To determine if these signatures were also evident in patient-derived organoid (PDO) models, we analyzed microarray data available from four recently generated PDOs, three of which were derived from well-to-moderately differentiated tumors (19T, 1T, 24T) and one that was derived from a moderately-to-poorly differentiated tumor (9T) ([@bib37]). Expression of the epithelial genes *CLDN4, EPCAM, TJP3,* and *KRT19* was highest in the well-to-moderately differentiated organoids, whereas expression of the mesenchymal genes *TGFB1, ZEB1, FN1,* and *CALD1* was highest in the 9T organoid ([Figure 4](#fig4){ref-type="fig"}D), demonstrating the cell-line-derived gene expression signature of tumor histology is also evident in organoid models of the disease.

Finally, to determine if primary BTCs harboring these signatures could be identified, 35 primary BTCs profiled by the TCGA were clustered with the cell lines based on the EMT signature. This analysis identified two primary BTCs that clustered with the mesenchymal lines and eight primary tumors that clustered with the epithelial lines ([Figure S5](#mmc1){ref-type="supplementary-material"}). Notably, examination of the histopathology of the primary tumors in the mesenchymal cluster confirmed that case TCGA-ZU-A8S4 was a sarcomatoid carcinoma showing spindle cell (mesenchymal) morphology with no evidence of gland formation, whereas case TCGA-W5-AA2H showed some gland formation but also a high degree of tumor budding, forming small clusters of spindle shaped tumor cells ([Figure S6](#mmc1){ref-type="supplementary-material"}). Comparatively, all eight primary cases that clustered with the epithelial lines showed clear evidence of gland formation and epithelioid cell morphology, without spindle cells or tumor budding ([Figure S6](#mmc1){ref-type="supplementary-material"}).

Investigation of Actionable Genetic Alterations in BTC {#sec2.6}
------------------------------------------------------

### IDH1^R132C^ Mutation {#sec2.6.1}

We identified one cell line (SNU-1079, intrahepatic) harboring an *IDH1* ^R132C^ hotspot mutation, which was confirmed using Sanger sequencing ([Figure S7](#mmc1){ref-type="supplementary-material"}A inset). Consistent with the neomorphic advantage conferred by this mutation ([@bib45]), levels of the oncometabolite R-2-hydroxy-glutarate (2-HG) were markedly elevated in culture medium and cell pellets from this line ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Treatment of SNU-1079 cells with the mutant IDH1 inhibitor AGI-5198 significantly decreased 2-HG accumulation ([Figure S7](#mmc1){ref-type="supplementary-material"}B); however, neither AGI-5198 nor the clinically used derivative AG-120 (ivosidenib) inhibited proliferation of this line ([Figure S7](#mmc1){ref-type="supplementary-material"}C). To determine whether similar effects occurred in PDOs, we determined the effect of AG-120 in the 9T PDO, generated from a patient with an *IDH1*^*R132L*^ mutant intrahepatic cholangiocarcinoma. As observed in SNU-1079 cells, AG-120 failed to inhibit growth of the *IDH1*^*R132L*^ organoid, with instead a modest but significant increase in cell proliferation observed ([Figure S7](#mmc1){ref-type="supplementary-material"}D).

Recent studies have suggested that mutant *IDH* may promote cholangiocarcinoma development by suppressing *HNF4A* expression and blocking hepatocyte differentiation ([@bib36]), and initial data from clinical trials of AG-120 in *IDH1* mutant cholangiocarcinoma have reported an upregulation of liver-specific genes in serial biopsy samples ([@bib15]). However, treatment of SNU-1079 cells with AGI-5198 or AG-120 failed to increase expression of *HNF4A* or other hepatocyte markers (*MGST1, CYP27A1, ALB*) or markers of epithelial (*EPCAM*) or mesenchymal (*VIM*) transition ([Figure S7](#mmc1){ref-type="supplementary-material"}E). Finally, as increased benefit of *IDH1* mutant BTCs to chemotherapy was recently reported ([@bib28]), we assessed the sensitivity of this line to gemcitabine. Although SNU-1079 cells were not exquisitely sensitive to gemcitabine, it ranked among the more sensitive lines ([Figure S7](#mmc1){ref-type="supplementary-material"}F). However, pre-treatment of SNU-1079 cells with AGI-5198 did not further enhance sensitivity, suggesting the sensitivity of *IDH*-mutant tumors to chemotherapy may not be directly related to elevated 2-HG levels ([Figure S7](#mmc1){ref-type="supplementary-material"}G).

### ERBB2 Mutation and Amplification {#sec2.6.2}

Mutations in the ERBB family of receptor tyrosine kinases, particularly *ERBB2* and *ERBB3,* occur in ∼10% of BTCs and we identified one cell line, TGBC18TKB, which carried two hotspot mutations in *ERBB2* (*S310F* and *R678Q*) ([Figure 5](#fig5){ref-type="fig"}A), which have been previously reported in primary BTC ([@bib24]). Notably, mRNA expression of ERBB2 was also highly elevated in TGBC18TKB cells ([Figure 5](#fig5){ref-type="fig"}B). We also identified a second cell line, TKKK, with highly elevated levels of ERBB2 mRNA ([Figure 5](#fig5){ref-type="fig"}B). Copy number analysis of this cell line revealed an amplification in *ERBB2* ([Figure 3](#fig3){ref-type="fig"}A), which was confirmed by qRT-PCR and *in situ hybridization* ([Figures 5](#fig5){ref-type="fig"}C and 5D). Importantly, both TGBC18TKB and TKKK cells were markedly more sensitive to the ERBB2 inhibitors lapatinib and AZD8931 compared with WT lines, establishing these mutations as potential drug targets in BTC ([Figures 5](#fig5){ref-type="fig"}E and 5F).Figure 5Characterization of *ERBB2* Mutant and Amplified BTC Cell Lines(A) Location of two *ERBB2* mutations in TGBC18TKB cells highlighted in red. Mutation plot from cBioPortal. Lollipops designate mutation points.(B) *ERBB2* mRNA expression in BTC cell lines determined by RNA-seq.(C and D) Validation of *ERBB2* amplification in TKKK cells by (C) q-RT-PCR--based DNA copy number analysis and (D) *in situ* hybridization (scale bar 5 μM). Values shown in C are mean ± SEM of a single sample assayed in technical triplicate.(E and F) Effect of the ERRB2 inhibitors (E) AZD8931 and (F) lapatinib on proliferation of *ERBB2* mutant/amplified and WT BTC cell lines. Cells were treated with drug for 72 h and cell proliferation determined by MTS assay. Values shown are mean ± SEM of a single experiment analyzed in quadruplicate. Similar results were obtained in two independent experiments. \*\*p \< 0.005, \*\*\*p \< 0.0005 compared with untreated controls, unpaired t test.

### ERK-MAPK Signaling Is Activated by Multiple Mechanisms in BTC Cell Lines {#sec2.6.3}

Integration of the exome sequencing data and DNA copy number analysis revealed multiple mechanisms of ERK/MAPK pathway activation in BTC cell lines. Specifically, *KRAS* mutations were identified in 8/22 cell lines, whereas amplification of *KRAS* was observed in three cell lines of which one line (NOZ) also harbored a *KRAS* mutation ([Table S5](#mmc1){ref-type="supplementary-material"}). In addition, we identified two cell lines harboring low-activity *BRAF* mutations (TGBC18TKB, *BRAF*^*I581L,\ N582T*^, and Sk-Ch-A1, *BRAF*^*D594T*^) ([Table S5](#mmc1){ref-type="supplementary-material"}). Unlike activating *BRAF* mutations (V600E), these mutants act as amplifiers of RAS signaling and often coexist with other forms of RAS activation ([@bib48]). The identification of *ERBB2* hotspot mutations in TGBC18TKB cells ([Figure 5](#fig5){ref-type="fig"}A) is consistent with this mechanism. Similarly, we identified a truncating mutation in *RASA1* in Sk-Ch-A1 cells ([Table S2](#mmc2){ref-type="supplementary-material"} and [Figure S1](#mmc1){ref-type="supplementary-material"}), which encodes the Ras GTPase-activating protein p120-RasGAP, which suppresses RAS signaling by converting RAS to the inactive GDP-bound form ([@bib23]).

We also identified one cell line (KKU-M055) with a K57N mutation in *MAP2K1* (*MEK1*), which has been previously observed in lung adenocarcinoma and melanoma ([Figure 6](#fig6){ref-type="fig"}A). As with low-activity *BRAF* mutations, *MAP2K1*^*K57N*^ was recently classified as a class II MEK mutant, which is partially dependent on upstream RAF to drive ERK signaling and likely acts as an amplifier of RAS signaling ([@bib10]). Notably, compared with *MEK*^*WT*^ G415 cells, *MEK*^*K57N*^ mutant KKU-M055 cells were highly resistant to growth inhibition or signaling inhibition induced by the allosteric MEK inhibitor trametinib or the ERK inhibitor SCH772984 ([Figures 6](#fig6){ref-type="fig"}B--6E). Time course experiments also demonstrated that SCH772984 increased levels of active CRAF (pCRAF S338) in both *MAP2K*^*K57N*^ mutant and WT cell lines ([Figure 6](#fig6){ref-type="fig"}F), which is an expected effect of this drug due to relief of ERK-mediated inhibitory phosphorylation of CRAF ([@bib8]). However, although pERK levels remained suppressed in MEK^WT^ G415 cells after 6 h, they were strongly reactivated in *MEK*^*K57N*^ mutant KKU-M055 cells, consistent with the *MAP2K*^*K57N*^ acting to amplify BRAF/MAPK/ERK signaling ([Figure 6](#fig6){ref-type="fig"}F).Figure 6Characterization of *MEK1*^*K57N*^ Mutant Cell Line(A) Mutation plot from cBioPortal showing location and frequency of occurrence of *MEK*^*K57N*^ mutation in human cancers. Lollipops designate mutation points.(B and C) MTS assays of a *MEK*^*K57N*^-mutant (KKU-M055) and a *MEK*^WT^ cell line (G415) treated with (B) the MEK inhibitor trametinib or (C) the ERK inhibitor SCH772984 for 72 h. Values shown are mean ± SEM from a single experiment performed in quadruplicate. Similar results were obtained in two independent experiments.(D and E) Effect of (D) trametinib or (E) SCH772984 on pERK protein levels in *MEK*^*K57N*^ mutant and *MEK*^*WT*^ cell lines. Cells were treated with drug for 24 h and pERK levels determined by Western blot. MW (molecular weight markers) in Kilo Daltons.(F) Time course Western blot analysis of the effect of ERK inhibitor (SCH772984, 500 nM) treatment on pERK and pCRAF protein levels in MEK^K57N^ mutant (KKU-M055) and *MEK*^*WT*^ G415 cells.

The role of *MAP2K*^*K57N*^ as an amplifier of RAS signaling suggested KKU-M055 cells may also harbor alterations in upstream components of the RAS/MAPK pathway. As no mutations in *RAS, BRAF, NF1,* and *RASA1* were present, we investigated mRNA expression of the major receptor tyrosine kinases (RTKs), which revealed marked overexpression of FGFR1 in this cell line ([Figure 7](#fig7){ref-type="fig"}A). Furthermore, KKU-M055 cells were highly sensitive to the FGFR inhibitors BGJ398 and erdafitinib both *in vitro* and *in vivo* ([Figures 7](#fig7){ref-type="fig"}B--7E), suggesting proliferation of KKU-M055 cells is driven by FGFR1, with the *MEK*^*K57N*^ mutation likely acting to amplify FGFR-driven MAPK signaling.Figure 7Characterization of FGFR Overexpressing BTC Cell Lines(A) Basal (Top) mRNA and (Bottom) protein expression of *FGFR1* in the BTC cell line panel determined by qPCR and Western blot. M (molecular weight markers) in Kilo Daltons. Values shown in the top panel are mean + SEM from a single experiment performed in technical triplicate.(B and C) Response of *FGFR1* overexpressing KKU-M055 cells and non-overexpressing G415 cells to increasing concentrations of (B) BGJ398 and (C) erdafitinib. Cells were treated for 72 h and cell growth determined by MTS assays. Values shown are mean ± SEM from a single experiment performed in quadruplicate. Similar results were obtained in three independent experiments.(D and E) Response to KKU-M055 cells to erdafitinib *in vivo*. (D) Mice (n = 4 per group) were each injected with tumour cells in their right and left flanks and treated once daily via oral gavage with either erdafitinib (20 mg/kg) or vehicle (20% hydroxypropyl b cyclodextrin) for 18 consecutive days. Values shown in panel D are mean +/- SEM. (E) Representative images of resected tumours from mice treated with vehicle or erdafitanib.(F and G) mRNA expression of (F) *FGFR3* and (G) *FGFR4* in the BTC cell line panel determined by RNA-seq. FGFR3/4 overexpressing Mz-Ch-A2 cells are shown in blue.(H) *FRS2* DNA copy number in BTC cell lines.(I and J) Response of FGFR3/4 overexpressing (blue) and non-overexpressing cell lines (black) to (I) BGJ398 and (J) erdafitinib *in vitro*. Cells were treated with drug for 72 h and cell growth determined by MTS assays. Values shown are mean +/- SEM from a representative experiment.

### FGFR3 and FGFR4 {#sec2.6.4}

Finally, we utilized the RNA-seq data to perform an outlier analysis in order to identify other cell lines that expressed exceptionally high levels of targetable receptor tyrosine kinases. This approach identified high levels of *FGFR3* and *FGFR4* mRNA in Mz-ChA-2 cells ([Figures 7](#fig7){ref-type="fig"}F and 7G). Interrogation of the signaling components downstream of FGFR in this cell line also revealed a focal low-level amplification of the FGFR docking protein *FRS2* ([Figure 7](#fig7){ref-type="fig"}H) ([@bib41]). Treatment of Mz-ChA-2 cells with the FGFR inhibitors BGJ398 and erdafitinib induced exquisite sensitivity to both inhibitors compared with non-overexpressing lines ([Figures 7](#fig7){ref-type="fig"}I and 7J).

Discussion {#sec3}
==========

BTCs are a genomically heterogeneous group of cancers featuring a substantial number of low prevalence mutations. In this study, we profiled the genomic landscape of 22 BTC cell lines derived from various anatomical locations in the biliary tract and demonstrate that the most commonly mutated driver genes, mutational signatures, and deletions and amplifications observed in primary tumors were also present in cell lines.

Cell lines exhibited a higher mutational burden to that reported in primary BTCs. This may be partly related to the lack of available normal genomic DNA for comparison. As a result, our somatic variant calling was dependent on comparisons to databases of known SNPs and germline mutations that may have overcalled the number of somatic mutations. Furthermore, cancer cell lines have undergone additional passages since the time of resection and hence have had the time to acquire additional mutations *in vitro.* Finally, it is possible that studies of primary BTC may under-call somatic variants, particularly tumors that have a high content of normal cells.

A major finding of the current study was the identification of sub classes of cell lines that differed primarily in the expression of genes involved in EMT, cell adhesion, differentiation, migration and developmental processes. Consistent with these transcriptional differences, the mesenchymal cluster was enriched for cell lines derived from metastatic gallbladder cancers, and morphological and histological analyses of the cell lines in this cluster revealed they were enriched for cell lines that had lost characteristics of epithelial differentiation. Importantly, we also observed similar differential expression of these epithelial/mesenchymal genes in tumor organoids derived from moderately and poorly differentiated tumors. The advancement of 3D culture technology is now enabling the generation of increasing numbers of PDO model systems for use in translational research, and comparison of cell line and organoid platforms is of increasing interest. In this regard, it is noteworthy that our initial comparisons of these models, albeit using small numbers, suggest reasonable overlap. Finally, intersection of the epithelial and mesenchymal signatures identified in cell lines with RNA-seq data available through the TCGA revealed the existence of primary BTCs harboring both signatures, indicating these signatures are applicable to primary tumors. Indeed, primary BTCs that have lost expression of epithelial markers or that have gained expression of mesenchymal markers have been previously reported and associated with poorer outcome ([@bib43], [@bib46]).

In comparison to our cell line analysis, prior gene expression profiling of primary BTCs identified four major groups of BTCs ([@bib17], [@bib29]), including a group characterized by high expression of cytokines and immune checkpoint molecules. Gene expression profiling of intrahepatic cholangiocarcinomas also identified two major subclasses characterized by expression of proliferative and inflammatory genes, respectively. The contribution of stromal and inflammatory cells to the transcriptional signature of primary cancers likely contributes to these subtypes not being observed in cell lines and highlights an advantage of analyzing cell line models to reveal insights into biological differences among samples that may otherwise be masked by strong stromal signatures.

The genomic analysis of the BTC cell lines also revealed a number of potential actionable targets. In this regard, we tested a series of therapeutic targets established in other cancers for which we identified the corresponding endogenous genetic change in a BTC cell line. We identified the *R132C* hotspot mutation in *IDH1* in the SNU-1079 line, which had corresponding high levels of the onco-metabolite 2-HG. Notably, this cell line had the lowest mutational load among the cell lines and interestingly did not harbor mutations in any other established tumor suppressor genes or oncogenes, consistent with a potential epigenetic mechanism of tumor promotion in *IDH* mutant cancers ([@bib9], [@bib44]). The inhibitor of mutant *IDH1*, AGI-5198, inhibits colony formation of glioma cells transformed with mutant *IDH1* ([@bib33]); however, despite lowering of 2-HG levels, AGI-5198 or its clinically used derivative AG-120, had no effect on proliferation of SNU-1079 cells. Similarly, we observed that a PDO harboring an *IDH1*^*R132L*^ mutation was also refractory to AG-120. These effects are consistent with pre-clinical studies in *IDH1* mutant chondrosarcoma ([@bib35]), as well as recent clinical evidence in cholangiocarcinoma where objective responses were only observed in 6% of *IDH1* mutant patients treated with AG-120 ([@bib25]). Notably, the outcomes of the ClarIDHy phase III trial were recently reported in which *IDH1* mutant cholangiocarcinoma patients treated with AG-120 (ivosidenib) experienced a significant improvement in progression-free survival (2.7 months) compared with patients treated with placebo (1.4 months) ([@bib1]). Consistent with our findings in pre-clinical models, objective response were rare (2.4%), raising the possibility that inhibition of mutant IDH1 may elicit anti-tumour activity through non-cell autonomous mechanisms. Indeed, the oncometabolite 2-HG has been previously reported to promote angiogenesis ([@bib38]) and suppress anti-tumour T cell immunity ([@bib5]).

On the other hand, we detected two cell lines harboring mutations and amplification of members of the ERBB receptor family, which demonstrated sensitivity to ERBB2-targeting agents. These findings are consistent with case reports and small clinical studies reporting clinical responses of BTCs to ERBB2 targeted agents ([@bib14], [@bib30]) and collectively support the fact that *ERBB2* amplification/mutations represent a promising therapeutic target in BTC.

An important finding of the current study is the identification of multiple mechanisms of ERK-MAPK pathway deregulation in BTC, whereby in addition to identifying mutations in *KRAS* in 36% of the cell lines, we identified *KRAS* amplifications in three lines, inactivating mutations in *BRAF* in two lines and a *MAP2K1*^*K57T*^ mutation in one cell line. Notably, both inactivating *BRAF* mutations and the *MAP2K1*^*K57T*^ mutation have been suggested to act as amplifiers of ERK-MAPK signaling and frequently co-exist with mutations in upstream components of the ERK-MAPK pathway ([@bib10], [@bib48]). Indeed, detailed investigation of the cell lines harboring these mutations identified a co-existent activating *ERBB2* mutation in *BRAF* mutant (*I581L, N582T*) TGBC18TKB cells, an inactivating *RASA1* mutation in *BRAF*-mutant Sk-ChA-1 cells, and high levels of FGFR1 expression in *MAP2K1*^*K57N*^ mutant KKU-M055 cells. An important implication of these findings is that tumors found to harbor low-activity "amplifier mutations" in the MAPK pathway in commonly used cancer gene panel sequencing tests should be further interrogated for amplifications or overexpression of RTKs, as this may yield robust therapeutic targets. Proof of concept of this approach was our finding that *MAP2K1*^*K57N*^ mutant KKU-M055 cells express high levels of FGFR1 and are exquisitely sensitive to FGFR inhibition.

We also identified high levels of FGFR3 and FGFR4 expression in Mz-ChA-2 cells. Further interrogation of the FGFR signaling pathway in this line also revealed an amplification of *FRS2*, and Mz-Ch-A2 cells were highly sensitive to FGFR inhibition *in vitro*. This finding is consistent with observations in liposarcoma, where cell lines harboring *FRS2* amplifications have also been reported to be sensitive to FGFR inhibitors ([@bib49]). Importantly, gene fusions involving *FGFR2* occur in 7%--14% of intrahepatic cholangiocarcinomas ([@bib11], [@bib34]), and these tumors have been reported to be clinically responsive to FGFR inhibitors ([@bib16]). Although we did not identify any cell lines harboring *FGFR2* fusions, our findings suggest that the subset of BTCs driven by aberrant FGFR signaling and amenable to FGFR inhibition extend beyond those harboring *FGFR2* fusions alone.

In summary, we characterized the exome, copy number, and transcriptome of a large panel of BTC cell lines and demonstrated that at the genomic level these cell line represent accurate models of primary disease. We also demonstrated that BTC cell lines can be separated into two major groups based on their transcriptional profiles, which is primarily driven by differential expression of genes involved in epithelial differentiation and EMT and which are also observed in both PDOs and primary tumors. We also identify a number of potential actionable drug targets for this disease (*ERBB2, FGFR1, and FGFR3/4*) and others that require additional investigation (*IDH1*) and provide a resource to facilitate the ongoing discovery and validation of potential therapeutic targets in BTC.

Limitations of the Study {#sec3.1}
------------------------

An inherent limitation of the genomic analysis of historically established cell lines is the lack of normal genomic DNA for comparison, which may have resulted in miscalling of some genetic alterations. Cell lines also potentially acquire additional (epi-)genetic changes during passage, which may cause them to differ from primary tumors. Finally, the relatively small number of BTC cell lines available for genomic characterization is insufficient to capture all of genomic changes that drive BTC.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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